ArticleClinical ophthalmology (Auckland, N.Z.)2021
Management of Persistent Corneal Epithelial Defects with Human Amniotic Membrane-derived Dry Matrix.
Article in Clinical ophthalmology (Auckland, N.Z.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 31 citations in OpenAlex.
- Sutureless Dehydrated Amniotic Membrane (Omnigen) Application Using a Specialised Bandage Contact Lens (OmniLenz) for the Treatment of Dry Eye Disease: A 6-Month Randomised Control Trial.Medicina (Kaunas, Lithuania) · 2024Trial
- Historical controls and modelled costs cannot support first-line amniotic membrane for persistent epithelial defects.Eye (London, England) · 2026Article
- Management of ocular surface disease involving inflammation and persistent epithelial defects utilising various treatment modalities in the UK National Health Service (NHS).Eye (London, England) · 2026Article
- Surgical Management of Corneal Damage in Patients with Primary and Post-Surgical Eyelid Anomalies.Journal of clinical medicine · 2026Review
- Comparison of Effectiveness of Biovance Single and Triple Layer Decellularized Basement Membranes for Treatment of Ocular Surface Disease: A Retrospective Study.Clinical optometry · 2026Article
- Fungal Keratitis Following Application of Dehydrated Amniotic Membrane (Omnigen) With (OmniLenz) Bandage Contact Lens.Case reports in ophthalmological medicine · 2026Article
- Amniotic Membrane in Excimer Laser Surface Ablation (ELSA): Mechanisms for Haze Prevention and Broader Ocular Surface Optimisation.Ophthalmology and therapy · 2026Review
- Current and Emerging Approaches in the Management of Severe Ocular Surface Disease.Medicina (Kaunas, Lithuania) · 2025Review
- Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review of Ophthalmic Management and Treatment.Vision (Basel, Switzerland) · 2025Review
- A Narrative Review of Amniotic Membrane Transplantation in Ocular Surface Repair: Unveiling the Immunoregulatory Pathways for Timely Intervention.Ophthalmology and therapy · 2025Review
- Use of an Eyelid Pressure Patch Concomitantly with a Decellularized Dehydrated Amniotic Membrane for Ocular Surface Disease Management.Ophthalmology and therapy · 2025Article
- Shield ulcer in keratoconus in the absence of atopic or vernal kerato-conjunctivitis.GMS ophthalmology cases · 2025Article
- Sutureless-dehydrated amniotic membrane (Omnigen®) mounted on contact lens (OmniLenz®) in the treatment of small corneal perforations secondary to exposure keratitis in ICU patients.Medical hypothesis, discovery & innovation ophthalmology journal · 2025Article
- Foxp3Experimental eye research · 2024Article
- Herpes simplex keratitis: A brief clinical overview.World journal of virology · 2024Review
- Bilateral Crosslinking with Glutaraldehyde and 1-Ethyl-3-(3-Dimethylaminopropyl) Carbodiimide: An Optimization Strategy for the Application of Decellularized Human Amniotic Membrane in Tissue Engineering.Journal of tissue engineering and regenerative medicine · 2024Article
- Management of Ocular Surface Inflammation with Persistent Epithelial Defects Using a Sutureless Human Amniotic Membrane Dehydrated Matrix: A Prospective Study Utilizing a Digital Ocular Surface Assessment Tool.Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- Bilateral Sutureless Application of Human Dehydrated Amniotic Membrane with a Specialised Bandage Contact Lens for Moderate-to-Severe Dry Eye Disease: A Prospective Study with 1-Month Follow-Up.Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine.Gynecologic oncology reports · 2023Review
- The developments in amniotic membrane transplantation in glaucoma and vitreoretinal procedures.International ophthalmology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo report the outcomes of using human amniotic membrane-derived dry matrix (AMDDM) in the management of persistent corneal epithelial defects (PEDs) of various etiologies.
methodsA cohort study of 84 patients age range 7 to 92 years with 93 PEDs were treated with AMDDM (Omnigen
resultsA total of 106 applications of AMDDM were recorded for 81 patients (52 males, 29 females) with a spectrum of different etiologies. Fifty-eight percent of the eyes showed complete healing, and 28% showed partial decrease of the size of PEDs with average treatment length recorded as 22.4±12.3 days. In patients with limbal stem cell deficiency (n=44; aniridia=12, chemical injury=9, Stevens-Johnson syndrome=10), 50% of PEDs showed complete healing and 27% showed partial healing. In patients with microbial keratitis (n=21) (bacterial: 13, fungal: 4, herpetic: 3,
conclusionAMDDM can be easily applied in the clinical setting and has demonstrated its efficiency as a new tool to treat persistent epithelial defects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.